STOCK TITAN

Movano Strengthens Intellectual Property for its Non-Invasive Sensor Technology with Three New U.S. Patents

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Movano Inc. (Nasdaq: MOVE) announced the award of three new U.S. patents, bringing its total to six. The patents focus on non-invasive sensor technology that combines Radio Frequency (RF) and mmWave capabilities into a single Integrated Circuit (IC) for future wearable devices. With over 40 pending applications, the company aims to provide health metrics like glucose and blood pressure. CEO John Mastrototaro emphasized that these innovations will enhance data accuracy and differentiate Movano’s products in the market.

Positive
  • Increase in total issued U.S. patents to six.
  • Over 40 pending U.S. and International patent applications.
  • Focus on innovative non-invasive sensor technology for health monitoring.
Negative
  • None.

PLEASANTON, Calif., Jan. 27, 2022 /PRNewswire/ -- Movano Inc. (Nasdaq: MOVE), a health technology company designing devices that inspire and empower you to live a healthier, happier life, announced it has been awarded three new U.S. patents, increasing its total number of issued U.S. patents to six. The Company also has more than 40 pending U.S. and International applications. The patents and pending patent applications are related to innovations around Movano's non-invasive sensor technology, which combines Radio Frequency (RF) and mmWave capabilities onto a single Integrated Circuit (IC) that will be integrated into various wearable devices in the future.

"As Movano progresses toward bringing RF-enabled, non-invasive health wearables that will measure glucose, blood pressure and other vital health data to the market, we have been prolifically filing patents to protect our core technology," said Dr. John Mastrototaro, CEO of Movano Inc. "Over the past several years, we have been building an innovative architecture for a single multi-band IC in order to provide health conscious consumers with accurate health data. We've developed, and now patented, innovations that utilize unprecedented signal diversity and advanced signal processing capabilities to produce rich data sets that will allow us to deliver on these promises and differentiate from the competition."

For more information about Movano, please visit https://movano.com/ or https://ir.movano.com/

About Movano

Founded in 2018, Movano Inc. is a health technology company creating simple, smart and personalized devices designed to inspire and empower individuals on their health journey live a happier, healthier life. Movano's technology is being developed to provide vital health information, including glucose and blood pressure data, in a variety of form factors to meet individual style needs and give users actionable feedback in order to improve the quality of their life. For more information, visit https://movano.com/.

Forward Looking Statements

This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development, clinical trial and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our registration statement on Form S-1, as amended, and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors."  Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/movano-strengthens-intellectual-property-for-its-non-invasive-sensor-technology-with-three-new-us-patents-301469329.html

SOURCE Movano

FAQ

What are the key highlights of Movano's recent patent announcement?

Movano announced three new U.S. patents, increasing its total to six, focusing on non-invasive sensor technology for health monitoring.

How many pending patent applications does Movano have?

Movano has over 40 pending U.S. and International patent applications.

What technology does Movano's new patents involve?

The new patents involve non-invasive sensor technology combining Radio Frequency (RF) and mmWave capabilities into a single Integrated Circuit.

What vital health data will Movano's technology measure?

Movano's technology aims to measure glucose, blood pressure, and other vital health data.

What is the stock symbol for Movano Inc.?

The stock symbol for Movano Inc. is MOVE.

Movano Inc.

NASDAQ:MOVE

MOVE Rankings

MOVE Latest News

MOVE Stock Data

21.17M
6.63M
17.33%
13.7%
0.39%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
PLEASANTON